UK Markets close in 4 hrs 4 mins

Merck & Co., Inc. (MRK)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
80.06-0.08 (-0.10%)
At close: 4:03PM EST

80.31 +0.25 (0.31%)
Before hours: 7:15AM EST

Full screen
Trade prices are not sourced from all markets
Previous close80.14
Open80.14
Bid80.10 x 1100
Ask80.42 x 800
Day's range79.60 - 80.46
52-week range65.25 - 92.64
Volume5,074,498
Avg. volume8,383,334
Market cap202.554B
Beta (5Y monthly)0.43
PE ratio (TTM)17.68
EPS (TTM)4.53
Earnings date04 Feb 2021
Forward dividend & yield2.60 (3.25%)
Ex-dividend date14 Dec 2020
1y target est95.58
  • 3 Cheap Stocks to Buy Before the Economy Makes a Full Recovery
    Motley Fool

    3 Cheap Stocks to Buy Before the Economy Makes a Full Recovery

    Before the economy and struggling stocks completely recover, investors may want to consider buying shares of Merck (NYSE: MRK), JPMorgan Chase (NYSE: JPM), and American Airlines (NASDAQ: AAL), which could be performing a whole lot better a year from now. Healthcare company Merck has had a tough year, mostly because hospitals are deferring procedures and people aren't making their usual trips to the doctor's office. In its earnings release, Merck reported that the pandemic has negatively affected its pharmaceutical revenue to the tune of about $475 million during the past quarter and $2.1 billion since the start of the year.

  • Is Merck & Co (MRK) a Good Value Investor Stock Right Now?
    Zacks

    Is Merck & Co (MRK) a Good Value Investor Stock Right Now?

    Let's see if Merck & Co (MRK) stock is a good choice for value-oriented investors right now from multiple angles.

  • Merck (MRK) to Buy OncoImmune, Add Late-Stage COVID-19 Treatment
    Zacks

    Merck (MRK) to Buy OncoImmune, Add Late-Stage COVID-19 Treatment

    The acquisition of OncoImmune will boost Merck's (MRK) portfolio with CD24Fc, a candidate in phase III studies for the treatment of patients with severe and critical COVID-19.